Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, ...
Aug 5, 2021
0
238
Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs). An overall histology-dependent survival was also ...
Oct 10, 2018
0
1
Low-dose aspirin may improve survival odds for patients battling head/neck and lung cancer, two new studies suggest.
Sep 23, 2019
0
2
A study conducted at the University of Turku, Finland, shows that plixorafenib, a new drug developed for treating melanoma and lung cancer, may also stop the progression of cutaneous squamous cell carcinoma.
Nov 22, 2023
0
56
Investigators from UCLA Jonsson Comprehensive Cancer Center have identified a germline biomarker signature that successfully predicts which patients will suffer serious side effects that occur in up to 3 in ten patients on ...
Feb 3, 2022
0
29
Overactivity of a protein that normally cues cells to divide sabotages the body's natural cellular recycling process, leading to heightened cancer growth and chemotherapy resistance, UT Southwestern Medical Center researchers ...
Sep 18, 2013
0
0
Researchers from several major U.S. universities and ITMO University in Russia have identified a number of new driver mutations in lung cancer cells that may be responsive to genomically targeted therapies and to immunotherapy.
May 10, 2016
0
29
Professor Wenbiao Hu from the QUT School of Public Health and Social Work said the team had looked at the possible influence of environmental changes given that liver cancer had increased in the face of decreases in known ...
Jan 19, 2023
0
5
Chugai Pharmaceutical announced today that the preclinical study findings on its original bispecific antibody ERY974, a molecule that binds Glypican-3 and CD3 simultaneously, and that is currently under development as a Phase ...
Oct 5, 2017
0
1
A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. ...
Jan 18, 2022
0
10
